Prostate tumor-initiating cells: A new target for telomerase inhibition therapy?
Prostate tumor-initiating cells: A new target for telomerase inhibition therapy?
复制标题
DOI：
10.1016/j.bbadis.2009.02.012
复制
发表时间：
2009-04-01
影响因子：
6.2
通讯作者：
Shay, Jerry W.
中科院分区：
文献类型：
--
作者：
Marian, Calin O.;Shay, Jerry W.
前列腺癌的常规疗法，特别是在其雄激素非依赖性形式中，可能导致具有肿瘤引发潜力的抗性细胞的小群体存活。这些“癌症干细胞”被认为是癌症复发的原因，靶向这些细胞的治疗策略非常重要。端粒酶是一种负责端粒延长的核糖核蛋白酶，在包括前列腺癌在内的大多数恶性肿瘤中被激活，但在大多数正常细胞中不存在。假定的肿瘤起始细胞具有显著水平的端粒酶，表明它们是端粒酶抑制治疗的极好靶点。在这篇综述中，我们提出了一些证据的假设，即传统疗法（标准化疗和/或放疗）与端粒酶抑制剂相结合，可能会导致有效和更持久的反应。(C)2009 Elsevier B. V.保留所有权利。
Conventional therapies for prostate cancer, especially in its androgen-independent form, may result in the survival of small populations of resistant cells with tumor-initiating potential. These "cancer stem cells" are believed to be responsible for cancer relapse, and therapeutic strategies targeting these cells are of great importance. Telomerase is a ribonucleoprotein enzyme responsible for telomere elongation and is activated in the majority of malignancies, including prostate cancer, but is absent in most normal cells. Putative tumor-initiating cells have significant levels of telomerase, indicating that they are an excellent target for telomerase inhibition therapy. In this review, we present some evidence for the hypothesis that conventional therapies (standard chemotherapy and/or radiation therapy) in combination with telomerase inhibitors may result in effective and more durable responses. (C) 2009 Elsevier B.V. All rights reserved.